Objective: Reflux oesophagitis (RO) is one of the most common diseases encountered by gastroenterologists and primary care physicians. However, few epidemiological studies have investigated the association of medication use and RO. This study aimed to investigate the prevalence of RO and its risk factors, particularly with respect to medication use.
Methods: This retrospective, cross-sectional study included consecutive patients who underwent oesophagogastroduodenoscopy (OGD) and were assessed using questionnaires at the National Center for Global Health and Medicine (Shinjuku, Tokyo, Japan) between October 2015 and December 2021. The questionnaire collected data on patient characteristics, medical history, smoking and alcohol consumption, and medications that patients were taking at the time of OGD.
Results: Among the 13 993 eligible patients, the prevalence of RO was 11.8%. Multivariate logistic regression analysis indicated that male sex (OR=1.52 (95% CI 1.35 to 1.72), p<0.001); obesity (OR=1.57 (95% CI 1.40 to 1.77), p<0.001); smoking (OR=1.19 (95% CI 1.02 to 1.38), p=0.026); alcohol consumption (OR=1.20 (95% CI 1.07 to 1.35), p=0.002); diabetes (OR=1.19 (95% CI 1.02 to 1.39), p=0.029); hiatal hernia (OR=3.10 (95% CI 2.78 to 3.46), p<0.001); absence of severe gastric atrophy (OR=2.14 (95% CI 0.39 to 0.56), p<0.001); and the use of calcium channel blockers (CCBs) (OR=1.22 (95% CI 1.06 to 1.40), p=0.007), theophylline (OR=2.13 (95% CI 1.27 to 3.56), p=0.004), and non-steroidal anti-inflammatory drugs (NSAIDs) (OR=1.29 (95% CI 1.03 to 1.61), p=0.026) were independent predictors of RO.
Conclusion: RO was present in 11.8% of patients. Use of CCBs, theophylline, and NSAIDs were independent predictors of RO.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bmjgast-2024-001468 | DOI Listing |
Dig Dis Sci
December 2024
Division of Gastroenterology & Hepatology, Penn State College of Medicine, Hershey, PA, 17033, USA.
Gastroesophageal reflux disease (GERD) is a very common condition characterized by chronic symptoms, such as heartburn or epigastric and/or substernal pain, that are frequently associated with mucosal damage resulting from abnormal reflux of gastric contents into the esophagus (Fass et al. in Nat Rev Dis Primers 7:55, 2021; Richter and Rubenstein in Gastroenterology 154:267-276, 2018). However, this damage can manifest in patients who do not exhibit typical GERD symptoms.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
December 2024
Esophageal Physiology Laboratory, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Background And Aims: The Lyon 2.0 consensus recommends 96-hr wireless pH studies for GERD diagnosis; however, the optimal length of pH-measurement has not been established. Further it is uncertain if, and under what circumstances, shorter recording times are sufficient for a conclusive diagnosis.
View Article and Find Full Text PDFBMJ Open Gastroenterol
December 2024
Department of Gastroenterology, National Center for Global Health and Medicine, Shinjuku-ku, Japan
Objective: Reflux oesophagitis (RO) is one of the most common diseases encountered by gastroenterologists and primary care physicians. However, few epidemiological studies have investigated the association of medication use and RO. This study aimed to investigate the prevalence of RO and its risk factors, particularly with respect to medication use.
View Article and Find Full Text PDFAsian J Endosc Surg
December 2024
Department of Surgery, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
Purpose: Double-tract reconstruction (DTR) is one of the major procedures following proximal gastrectomy (PG) with anti-reflex function for the esophagus. Although many studies demonstrated the feasibility of laparoscopic DTR, there is a lack of research on robotic DTR. We aimed to assess the safety and feasibility of robotic DTR following PG.
View Article and Find Full Text PDFJ Neurogastroenterol Motil
December 2024
Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, Korea.
Background/aims: Fexuprazan, a novel potassium-competitive acid blocker, was developed for treating acidrelated disorders. Pharmacokinetic and pharmacodynamic properties of fexuprazan, unlike those of proton pump inhibitors, are independent of food effect. This study aims to evaluate differences in efficacy and safety of fexuprazan in patients with erosive esophagitis (EE) according to the timing of dosing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!